Αρχική World News Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small Cell...

Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small Cell Lung Cancer

The addition of CS1001, a monoclonal antibody against PD-L1, to platinum-based chemotherapy significantly prolonged progression-free survival (PFS) over chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC), according to phase III findings presented at the ESMO Asia Virtual Congress 2020, held from 20 to 22 November 2020.

Caicun Zhou of the Department of Oncology, Shanghai Pulmonary Hospital in Shanghai, China presented findings on behalf of fellow investigators from a pre-planned analysis of PFS data from the randomised, double-blind, phase III GEMSTONE-302 (NCT03789604) study comparing the efficacy and safety of first-line chemotherapy with and without CS1001 in advanced NSCLC.

CS1001 is a full-length, fully human IgG4 monoclonal antibody that targets PD-L1. Previous reports found that it was well-tolerated and showed promising anti-tumour activity across a range of cancers, including NSCLC.

Patients with advanced NSCLC who had received no previous systemic therapy for metastatic disease, were stratified by histology (squamous versus non-squamous), PD-L1 expression levels (≥1% versus <1%), and ECOG performance status (0 versus 1).

Following 2:1 randomisation, 320 patients received CS1001 by i.v. at 1200 mg every 3 weeks and 159 patients received placebo; both groups also were treated with platinum-based chemotherapy for up to 4 cycles, followed by a maximum 2 years of maintenance with either CS1001 or placebo. Pemetrexed was also given as maintenance therapy to patients with non-squamous NSCLC.

Investigator-assessed PFS by RECIST v1.1 served as the primary endpoint.

The addition of CS1001 to chemotherapy significantly increased patient benefit

Baseline characteristics were balanced between the two treatment arms.

As of 8 June 2020, the median follow-up was 8.67 and 8.34 months in the CS1001 and placebo arms, respectively.

A significant PFS improvement was observed with CS1001 plus chemotherapy over placebo/chemotherapy; the median PFS was 7.8 versus 4.9 months (stratified hazard ratio [HR] 0.50; 95% confidence interval [CI] 0.39-0.64; p < 0.0001).


Investigator-assessed progression-free survival, the primary endpoint of GEMSTONE-302 study.

© Caicun Zhou.

The objective response rate (ORR) was 61.4% with CS1001/chemotherapy compared to 39.2% with placebo/chemotherapy.

Although overall survival (OS) data were immature, a trend towards prolonged OS was observed with the respective treatments, where median OS was not reached versus 14.75 months (stratified HR 0.66; 95% CI 0.44-0.97).

Subgroup analyses demonstrated similar clinical benefit with the addition of CS1001 across squamous versus non-squamous histology and PD-L1 expression levels.

Both treatments showed similar safety profiles, with the exception of the occurrence of immune-related adverse events (AEs) in the CS1001/chemotherapy arm that were mostly grades 1 and 2. Grade ≥3 AEs were reported in 61.9% of patients receiving CS1001 and 61.6% of patients receiving placebo. No new unexpected safety signals were found.


The authors pointed out it was the first phase III study conducted in China for an anti-PD-L1 monoclonal antibody plus chemotherapy in treatment-naive patients with advanced, squamous or non-squamous NSCLC.

These findings demonstrated that CS1001 combined with chemotherapy provided a statistically significant and clinically meaningful PFS benefit together with a well-tolerated safety profile compared to chemotherapy across subgroups with different histology and PD-L1 expression levels.

The authors predicted that CS1001 plus chemotherapy will potentially become a new standard of care for the first-line treatment of advanced NSCLC after receiving regulatory approval.

Funding for this study was reported from CStone Pharmaceuticals.


LBA4 – Zhou C, Wang Z, Sun Y, et al. GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PD-L1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC). ESMO Asia Virtual Congress 2020 (20-22 November).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...